Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.

Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
TUSTIN, CA–(Marketwire – 07/13/10) – Radient Pharmaceuticals Corporation (RPC) (AMEX: RPC – News ) announced today that it has entered into a letter of intent (LOI) to acquire Provista Diagnostics Inc. (PDI), a Nevada corporation offering laboratory testing services that meet the Clinical Laboratory Improvement Act (CLIA) guidelines. Radient Pharmaceuticals intends to acquire PDI, in a stock …

Read more on Marketwire via Yahoo! Finance